AbbVie (ABBV) Depreciation & Amortization (CF) (2016 - 2025)
AbbVie (ABBV) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $203.0 million as the latest value for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 1.46% to $203.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $762.0 million through Dec 2025, changed 0.26% year-over-year, with the annual reading at $762.0 million for FY2025, 0.26% changed from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $203.0 million at AbbVie, up from $192.0 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $223.0 million in Q3 2021, with the low at $173.0 million in Q4 2021.
- Average Depreciation & Amortization (CF) over 5 years is $193.0 million, with a median of $191.5 million recorded in 2024.
- Peak annual rise in Depreciation & Amortization (CF) hit 79.13% in 2021, while the deepest fall reached 23.79% in 2021.
- Over 5 years, Depreciation & Amortization (CF) stood at $173.0 million in 2021, then rose by 13.29% to $196.0 million in 2022, then fell by 4.59% to $187.0 million in 2023, then rose by 10.16% to $206.0 million in 2024, then fell by 1.46% to $203.0 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $203.0 million, $192.0 million, and $186.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.